UBS analyst Trung Huynh lowered the firm’s price target on Insmed (INSM) to $109 from $110 and keeps a Buy rating on the shares. Insmed’s print was straightforward, with building anticipation into a catalyst-rich period, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed Reports Strong Q1 2025 Growth and Progress
- Insmed’s Promising Pipeline and Strong Financials Justify Buy Rating
- Insmed’s Strategic Growth and Pipeline Progress Drive Buy Rating
- Insmed’s Promising Future: Buy Rating Backed by Brensocatib Launch and Strong Clinical Pipeline
- Insmed’s Earnings Call: Strong Growth and Optimistic Outlook